Where is Novartis located in Canada?
Dorval, Quebec
Novartis Pharmaceuticals Canada Inc. is a leading research-based company with a wide-ranging program for the development and marketing of innovative prescription medications in Canada. The Company’s national head office building, completed in 2003, is located in Dorval, Quebec.
Where is the headquarters of Novartis?
Basel, Switzerland
Novartis/Headquarters
How do I contact Novartis?
1 (888) 669-6682
Novartis/Customer service
How many countries is Novartis in?
Find contact information for our diverse teams, products and offices in 90 countries around the world.
Is Sandoz part of Novartis?
Sandoz is a division of the Novartis Group and a global leader in generic pharmaceuticals and biosimilars. The division was established in 2003, when Novartis united all of its generics businesses under the name Sandoz – a single global brand with a long history.
What vaccines does Novartis make?
Novartis, for instance, no longer has a vaccine business, but it does have one of the largest and most diverse manufacturing operations in the industry. So we are collaborating to help manufacture two different mRNA-based COVID-19 vaccines – the Pfizer-BioNTech vaccine and the CureVac vaccine – in our facilities.
What is Novartis top selling drug?
As it stands, Novartis’ 10 best-selling medications in 2018 include the following, according to the company’s site:
- Gilenya.
- Cosentyx.
- Lucentis.
- Tasigna.
- Sandostatin.
- Gleevec/Glivec.
- Afinitor/Votubia.
- Galvus.
Which country owns Novartis?
Switzerland
Headquartered in Basel, Switzerland, Novartis has only been in existence in its current guise since 1996. However its roots go a long way back: it was created through the merger of two top Swiss companies, Ciba-Geigy and Sandoz Laboratories, in what some say has been the “most successful pharma merger”.
Who owns Novartis drug company?
In March 2018, GlaxoSmithKline announced that it has reached an agreement with Novartis to acquire Novartis’ 36.5 percent stake in their Consumer Healthcare Joint Venture for $13 billion (£9.2 billion).
